Logo

Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors

Share this

Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors

Shots:
  • Henry to get an exclusive option to license US patent application 14/654-140 for Galectin-3 inhibitors and will acquire minority equity in G3 Pharmaceuticals
  • The focus of the agreement is to advance therapies for heart failure with preserved ejection fraction (HFpEF) without no approved treatments
  • Galectin-3 is a protein for oral use and is indicated for the treatment of diastolic heart failure also known as HFpEF
  Ref: PRNewsWire | Image: LinkedIn

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions